HIV Infection Clinical Trial
Official title:
Adefovir Dipivoxil for the Treatment of Hepatitis B in Human Immunodeficiency Virus Infected Patients With Decompensated Hepatitis B Liver Disease and a Hepatitis B Viral Load of at Least 1.0 X 10(6) (Copies/mL) Despite 52 Weeks of Lamivudine Therapy
This study will evaluate the safety and effectiveness of adding the experimental drug
adefovir dipivoxil to lamivudine for treating hepatitis B virus (HBV) infection in
HIV-infected patients with liver cirrhosis. Adefovir inhibits HBV by interfering with
replication of the virus's genetic material. In some people, the drug has been active
against strains of HBV that are resistant to lamivudine; it may also have some activity
against HIV.
HIV-infected patients 21 years of age and older with chronic hepatitis B infection and liver
cirrhosis who have received lamivudine treatment for at least 1 year may be eligible for
this 48-week study. Candidates will be screened with a complete medical history, blood tests
and a 24-hour urine collection. Blood tests include HLA typing (a test of genetic markers on
white blood cells that permit specialized immunology studies). Within 4 weeks, candidates
who appear eligible for the study will have a physical examination and medical history, an
abdominal ultrasound (imaging test using sound waves) to check for cancer of the liver,
chest X-ray and electrocardiogram (EKG). Blood and urine tests will also be done, and women
who can become pregnant will have a pregnancy test.
Patients who meet the study criteria and decide to participate will then start treatment
with one 10-mg adefovir pill per day by mouth. In addition, patients will continue to take
all other medications prescribed by their doctor. Follow-up clinic visits will be scheduled
as follows:
- Days 1, 3, 5, 7, 10 and 21 - Blood will be drawn for specialized immunology tests and
to measure blood levels of HIV and HBV.
- Weeks 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44 - Blood and urine (single sample)
tests will be done to determine the side effects of adefovir and its effect on the HBV
infection.
- Week 48 or early termination (end of study) - Blood tests (including tests for
hepatitis C and D), abdominal ultrasound and a 24-hour urine collection to evaluate
kidney function will be done.
- Monthly visits beyond week 48 - Based on the HBV response to treatment and the
availability of the drug from the sponsor, patients may be offered to extend their
treatment with adefovir. Those who continue will have monthly follow-up visits for
blood and urine (single sample) tests.
Status | Completed |
Enrollment | 30 |
Est. completion date | February 2004 |
Est. primary completion date | |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A and older |
Eligibility |
INCLUSION CRITERIA: Age greater than or equal to 18 years Infection with HBV with HBV viral load greater than or equal to 1.0 x 10(6) copies/mL by Roche assay at screen HIV-infected as documented by ELISA and Western Blot in NIAID clinic (any CD4/HIV viral load) Decompensated cirrhosis (Child-Pugh Score greater than or equal to 7: Class B or C cirrhosis) Class A with Score of 6 acceptable if secondary to ascites grading and not encephalopathy or laboratory abnormality (PT, albumin, bilirubin). Able to return to NIH for study visits Have a physician(s) outside of NIH who will provide routine, as well as HIV and liver specific, care. Receiving lamivudine at a dose of at least 100 mg qd for greater than or equal to one year prior to enrollment (with no dosing interruptions of greater than 1 month total in the previous year and no interruption in the 3 months prior to study entry) Serum creatinine less than 1.5 mg/dL Serum phosphorus greater than or equal to 2.2 mg/dL (normal range NIH 2.3-4.3 mg/dL) Neutrophil count greater than or equal to 1000 cells/mm(3) Platelets greater than or equal to 50,000/mm(3) Hemoglobin greater than or equal to 8.0 mg/dL ALT less than or equal to 287 (7 X the NIH upper limit of normal) Not pregnant or breast-feeding. Pregnancy test must be negative within two weeks prior to dosing with study medications. If capable of pregnancy: use of effective contraception during study: effective contraception methods include abstinence, surgical sterilization of either partner, barrier methods such as diaphragm, condom, cap or sponge, or use of hormonal contraception with an anti-HIV regimen that will not alter metabolism of hormonal contraception Willing and able to provide written informed consent Because liver disease can result in encephalopathy, willing to designate a person for durable power of attorney on the NIH form for medical research and medical care purposes at the NIH Clinical Center EXCLUSION CRITERIA: Prior use of ADV (outside of patient receiving adefovir from NIH under emergency use IND) or prior use of tenofovir, or cidofovir Active serious systemic infections other than HIV or HBV Liver disease caused by reasons other than hepatitis B e.g., HCV, HDV, Wilson's, hemochromatosis, autoimmune hepatitis (ANA greater than or equal to 160) except history of drug-associated hepatitis with discontinuation of causative agent History of significant encephalopathy History of clinically significant pancreatitis History of untreated varices New AIDS-defining event other than esophageal candidiasis diagnosed within one month prior to baseline Decompensated heart failure Treatment with immunomodulator drugs (interferons, interleukins, corticosteroids in greater than physiologic doses) in the 4 weeks prior to baseline. G-CSF and epoietin use are permitted. Anti-HBV therapy other than lamivudine (such as emtricitabine, lobucavir, entecavir, HBIG, clevudine, MCC-478) with the exception of interferon alpha, famciclovir or foscarnet that ended more than 12 weeks prior to screen. Hepatic mass suggestive of hepatocellular carcinoma Alpha-fetoprotein level greater than or equal to 200ng/mL Evidence of gastrointestinal malabsorption or chronic nausea or vomiting Current alcohol or substance abuse that potentially could interfere with patient compliance Malignancy other than cutaneous Kaposi's sarcoma, skin cancer treated by resection or HPV-associated carcinoma in situ or Bowen's disease in the 5 years prior to enrollment History of clinically significant renal dysfunction within the previous 12 months prior to baseline Concomitant therapy with aminoglycosides, amphotericin B, cidofivir, cisplatinum, IV pentamidine, vancomycin, systemic chemotherapeutic agents, probenecid or other nephrotoxic agents Proteinuria (greater than or equal to 3+) ANA greater than or equal to 3 EU Positive PCR test for hepatitis C Antibodies to hepatitis D (delta hepatitis) Pregnancy or breast-feeding History of organ or bone marrow transplantation Any systemic illness that will make it unlikely that the subject will be able to return to NIH for the required study visits. |
Endpoint Classification: Safety/Efficacy Study, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | National Institute of Allergy and Infectious Diseases (NIAID) | Bethesda | Maryland |
Lead Sponsor | Collaborator |
---|---|
National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Colin JF, Cazals-Hatem D, Loriot MA, Martinot-Peignoux M, Pham BN, Auperin A, Degott C, Benhamou JP, Erlinger S, Valla D, Marcellin P. Influence of human immunodeficiency virus infection on chronic hepatitis B in homosexual men. Hepatology. 1999 Apr;29(4):1306-10. — View Citation
Honkoop P, de Man RA, Niesters HG, Zondervan PE, Schalm SW. Acute exacerbation of chronic hepatitis B virus infection after withdrawal of lamivudine therapy. Hepatology. 2000 Sep;32(3):635-9. — View Citation
Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med. 1998 Jul 9;339(2):61-8. — View Citation
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01805427 -
Antiretroviral Therapy and Extreme Weight
|
N/A |